 | Up a level |
Edelmann, J., Tausch, E., Landau, D. A., Robrecht, S., Bahlo, J., Fischer, K., Fink, A. M., Bloehdorn, J., Holzmann, K., Boettcher, S., Werner, L., Kneba, M., Gribben, J. G., Neuberg, D. S., Wu, C. J., Hallek, M., Doehner, H. and Stilgenbauer, S. (2017). Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia, 31 (3). S. 734 - 740. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Estenfelder, S., Tausch, E., Huber, H., Bloehdorn, J., Cymbalista, F., Leblond, V., Delmer, A., Ibach, S., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Pegourie, B., Seiler, T., Soekler, M., Zirlik, K., Alt, J., Schetelig, J., Hallek, M., Dreger, P., Doehner, H. and Stilgenbauer, S. (2016). MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY. Haematologica, 101. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Moehle, R., Loew, S., Binder, M., Atta, J., Keller, U., Wolf, H-H, Krause, S. W., Hess, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., Panse, J., Frickhofen, N., Roeth, A., Hader, C., Deckert, M., Fricker, H., Ihorst, G., Finke, J. and Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31 (4). S. 846 - 853. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hoster, E., Geisler, C. H., Doorduijn, J., van der Holt, B., Walewski, J., Bloehdorn, J., Ribrag, V., Salles, G., Hallek, M., Pott, C., Szymczyk, M., Kolstad, A., Laurell, A., Raty, R., Jerkeman, M., van't Veer, M., Kluin-Nelemans, J. C., Klapper, W., Unterhalt, M., Dreyling, M. and Hermine, O. (2016). Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia, 30 (6). S. 1428 - 1431. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Klymenko, T., Bloehdorn, J., Bahlo, J., Robrecht, S., Akylzhanova, G., Cox, K., Estenfelder, S., Wang, J., Edelmann, J., Strefford, J. C., Wojdacz, T. K., Fischer, K., Hallek, M., Stilgenbauer, S., Cragg, M., Gribben, J. and Braun, A. (2018). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia, 32 (2). S. 364 - 376. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Klymenko, T., Bloehdorn, J., Bahlo, J., Robrecht, S., Wang, J., Fischer, K., Akylzhanova, G., Edelmann, J., Estenfelder, S., Strefford, J., Wojdacz, T., Hallek, M., Stilgenbauer, S., Cragg, M., Gribben, J. and Braun, A. (2017). NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES. Haematologica, 102. S. 228 - 229. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Lohmann, G., Vasyutina, E., Bloehdorn, J., Reinart, N., Schneider, J. I., Babu, V., Knittel, G., Crispatzu, G., Mayer, P., Prinz, C., Muenzner, J. K., Biersack, B., Efremov, D. G., Chessa, L., Herling, C. D., Stilgenbauer, S., Hallek, M., Schobert, R., Reinhardt, H. C., Schumacher, B. and Herling, M. (2017). Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. Leukemia, 31 (5). S. 1177 - 1187. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Vasyutina, E., Boucas, J. M., Bloehdorn, J., Aszyk, C., Crispatzu, G., Stiefelhagen, M., Breuer, A., Mayer, P., Lengerke, C., Doehner, H., Beutner, D., Rosenwald, A., Stilgenbauer, S., Hallek, M., Benner, A. and Herling, M. (2015). The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia, 29 (10). S. 2003 - 2015. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551